Patent US5941868A successfully refreshed from Google Patents.
US5941868A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Localized intravascular delivery of growth factors for promotion of angiogenesis
Assignee: Beth Israel Deaconess Medical Center
•
Filing: 1996-11-22
•
Granted: 1999-08-24
•
Expires: 2016-11-22
Abstract
Abstract Angiogenesis in cardiac and other tissues is promoted by the transmural delivery of angiogenic factors such as VEGF, FGF, EGF, and PDGF, through blood vessels and other body lumens into the surrounding tissue. Usually, the angiogenic factor is delivered using a catheter having infusion parts at its distal end. Optionally, the distal end of the catheter is radially expanded to engage the infusion parts directly against the blood vessel wall.
Inventors
- 👤 Aaron V. Kaplan
- 👤 Michael Simons
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 12:34
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1858; A61K38/1808; A61K38/1825; A61K38/1866; A61M; A61M29/00; A61M29/02; A61P; A61P9/00; A61P9/10; A61M25/00; A61M25/10; A61M25/1002; A61M2025/1004; A61M2025/1043; A61M2025/105
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
27 words
A method for promoting angiogenesis in tissue surrounding a body lumen, said method comprising transmurally delivering an angiogenic factor at a target site within the body lumen.
Claim 2
Independent Claim
27 words
A method for promoting angiogenesis in tissue surrounding a body lumen, said method comprising transmurally delivering an angiogenic factor at a target site within the body lumen.
Claim 3
Dependent Claim
30 words
A method as in claim 1, wherein the angiogenic factor is selected from the group consisting of a VEGF polypeptide, an FGF polypeptide, an EGF polypeptide, and a PDGF polypeptide.
Claim 4
Dependent Claim
29 words
A method as in claim 1, wherein the angiogenic factor is delivered in an amount in the range from 0.1 μg to 100 mg per kilogram of body weight.
Claim 5
Dependent Claim
25 words
A method as in claim 1, wherein the angiogenic factor is delivered over a time period in the range from 1 second to 24 hours.
Claim 6
Independent Claim
61 words
A method for promoting angiogenesis in tissue surrounding a blood vessel, said method comprising: advancing a distal end of a catheter to a target site within the blood vessel; and delivering through the distal end of the catheter and transmurally through the blood vessel wall an amount of an angiogenic factor sufficient to promote angiogenesis in tissue surrounding the target site.
Claim 7
Independent Claim
61 words
A method for promoting angiogenesis in tissue surrounding a blood vessel, said method comprising: advancing a distal end of a catheter to a target site within the blood vessel; and delivering through the distal end of the catheter and transmurally through the blood vessel wall an amount of an angiogenic factor sufficient to promote angiogenesis in tissue surrounding the target site.
Claim 8
Dependent Claim
30 words
A method as in claim 5, wherein the angiogenic factor is selected from the group consisting of a VEGF polypeptide, an FGF polypeptide, an EGF polypeptide, and a PDGF polypeptide.
Claim 9
Dependent Claim
30 words
A method as in claim 5, wherein the angiogenic factor is delivered in an amount in the range from b 0.1 μg to 100 mg per kilogram of body weight.
Claim 10
Dependent Claim
25 words
A method as in claim 5, wherein the angiogenic factor is delivered over a time period in the range from 1 second to 24 hours.
Claim 11
Dependent Claim
27 words
A method as in claim 5, wherein the distal end of the catheter is introduced percutaneously to a patient's vasculature and advanced transluminally to the target site.
Claim 12
Dependent Claim
29 words
A method as in claim 9, wherein the angiogenic factor is delivered from the proximal end of the catheter, through a lumen in the catheter, to the distal end.
Claim 13
Dependent Claim
37 words
A method as in claim 5, further comprising expanding the distal end of the catheter to engage a plurality of infusion ports against the blood vessel wall wherein the angiogenic factor is delivered through said infusion port.
Claim 14
Dependent Claim
30 words
A method as in claim 11, wherein the expanding step comprises: positioning a balloon within the distal end of the catheter; and inflating the balloon to a predetermined inflation pressure.
Claim 15
Dependent Claim
35 words
A method as in claim 12, wherein the delivering step comprises supplying fluid containing the angiogenic factor to the ports at a predetermined infusion pressure, wherein the infusion pressure is independent of the inflation pressure.
Claim 16
Dependent Claim
39 words
A method as in claim 11, wherein the expanding step comprises inflating the distal end of the catheter having the infusion ports with a fluid carrying the angiogenic factor so that said fluid is released through the infusion ports.
Claim 17
Independent Claim
88 words
A method for promoting angiogenesis in tissue surrounding a stenotic region in a coronary artery, said method comprising: advancing transluminally a distal end of an infusion catheter to the stenotic region in the artery; radially expanding an array of infusion ports on the distal end of the infusion catheter to engage said ports against the luminal wall of the blood vessel; and delivering through the infusion ports into the blood vessel wall an amount of an angiogenic factor sufficient to promote angiogenesis in tissue surrounding the target site.
Claim 18
Independent Claim
88 words
A method for promoting angiogenesis in tissue surrounding a stenotic region in a coronary artery, said method comprising: advancing transluminally a distal end of an infusion catheter to the stenotic region in the artery; radially expanding an array of infusion ports on the distal end of the infusion catheter to engage said ports against the luminal wall of the blood vessel; and delivering through the infusion ports into the blood vessel wall an amount of an angiogenic factor sufficient to promote angiogenesis in tissue surrounding the target site.
Claim 19
Dependent Claim
30 words
A method as in claim 15, wherein the angiogenic factor is selected from the group consisting of a VEGF polypeptide, an FGF polypeptide, an EGF polypeptide, and a PDGF polypeptide.
Claim 20
Dependent Claim
29 words
A method as in claim 15, wherein the angiogenic factor is delivered in an amount in the range from 0.1 μg to 100 mg per kilogram of body weight.
Claim 21
Dependent Claim
25 words
A method as in claim 15, wherein the angiogenic factor is delivered over a time period in the range from 1 second to 24 hours.
Claim 22
Dependent Claim
28 words
A method as in claim 15, wherein the distal end of the catheter is introduced percutaneously to a patient's vasculature prior to transluminal advancement to the target site.
Claim 23
Dependent Claim
29 words
A method as in claim 19, wherein the angiogenic factor is delivered from the proximal end of the catheter, through a lumen in the catheter, to the distal end.
Claim 24
Dependent Claim
37 words
A method as in claim 15, further comprising expanding the distal end of the catheter to engage a plurality of infusion ports against the blood vessel wall, wherein the angiogenic factor is delivered through said infusion port.
Claim 25
Dependent Claim
32 words
A method as in claim 15, wherein the radially expanding step comprises: positioning a balloon within the distal end of the infusion catheter, and inflating the balloon to a predetermined inflation pressure.
Claim 26
Dependent Claim
36 words
A method as in claim 22, wherein the delivering step comprises supplying fluid containing the angiogenic factor to the infusion ports at a predetermined infusion pressure, wherein the infusion pressure is independent of the inflation pressure.
Claim 27
Dependent Claim
41 words
A method as in claim 15, wherein the radially expanding step comprises inflating the distal end of the infusion catheter having the infusion ports with a fluid carrying the angiogenic factor so that said fluid is released through the infusion ports.
References Cited (Backward Citations)
US5021044A
Cited
WO1990011734A1
Cited
US5049132A
Cited
US5180366A
Cited
WO1992011895A1
Cited
US5171217A
Cited
WO1993008866A1
Cited
US5244460A
Cited
WO1995005864A1
Cited
US5652225A
Cited
WO1996026742A1
Cited
WO1996039830A1
Cited
WO1997032990A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-08-23 | 2003-02-22 | 2003-08-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-08-23 | 2007-02-22 | 2007-08-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-08-23 | 2011-02-22 | 2011-08-24 | $7700.00 | Window Closed / Lapsed |